Eckert & Ziegler purchases Bioscan radiopharma unit

Eckert & Ziegler, a German-based isotope company, has acquired the radiopharmaceutical equipment business of Washington, D.C.-based Bioscan.

The transaction includes analytical instruments used in quality assurance of radioactive pharmaceuticals and automated radiopharmaceutical synthesis units, which are used worldwide for production of molecular imaging agents used in nuclear medicine, according to a release from the company. An Eckert & Ziegler board member said that investment will open up the company’s North American market. Meanwhile, Bioscan will focus on expanding its preclinical imaging product line, according to a spokesperson.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.